Antibody Drug Conjugate Market to Rise At 19% CAGR by 2023, according to Antibody Drug Conjugate Market 2019 Global Analysis To 2023 report published by Market Research Future. Antibody Drug Conjugate report anlayzes Market for Antibody Drug Conjugate by Type, Product, Technology, Application, region with Forecast To 2023.
—
Antibody Drug Conjugate Market to Rise At 19% CAGR by 2023, according to Antibody Drug Conjugate Market 2019 Global Analysis To 2023 report published by Market Research Future. Antibody Drug Conjugate report anlayzes Market for Antibody Drug Conjugate by Types (Monoclonal Antibodies, Linker), Product (Adcertis, Kadcyla) Technology (Immunogen Technology, Immunomedics Technology), Applications (Leukemia, Lymphoma) End-Users (Biotechnology Companies), region with Forecast To 2023.
Major Antibody Drug Conjugate Companies covered in the market report include Seattle Genetics (US), ImmunoGen, Inc. (US), Roche Holding AG (Switzerland), Genentech (US), Concortis Biotherapeutics (US), Agensys, Inc. (US), Antikor (UK), Immunomedics (US), Pfizer Inc. (US), Celldex Therapeutics (US), Millennium Pharmaceuticals (US), AbbVie Inc. (US), Bayer HealthCare (Germany), Astellas Pharma/Agensys (Japan), Progenics Pharmaceuticals (US), Mersana Therapeutics (US), Synthon (US), Heidelberg Pharma (Germany), Oxford BioTherapeutics (US), and others.
Free Sample “Antibody Drug Conjugate Market Research – Global Forecast till 2023” report at: https://www.marketresearchfuture.com/sample_request/1113
Global Antibody Drug Conjugate Market Highlights:
Antibody drug conjugates comprise three parts, mainly a specific antibody for binding, a cytotoxic agent designed to kill target cancer cells, and a chemical linker for attaching the cytotoxic agent to the antibody. These drug conjugates are regarded to be the new age of therapeutic agents. The combine effect of targeting specific types of cells and the killing ability of cytotoxic drugs make this drug conjugate the ideal one for treatment of various cancers.
There are many factors that is fueling the growth of the antibody drug conjugate market. The different market trends and factors in this market according to an analysis performed by Market Research Future (MRFR) include increasing prevalence of cancer, advancement in medical technology, increased investment in R & D, efficacy of ADC in treating diseases, rising collaboration amid biotechnology and biopharmaceuticals and research institutes, preclinical research, growing geriatric population and rise in obese population. On the contrary, the soaring cost related to the procedure may hamper the growth of the antibody drug conjugate market.
Global Antibody Drug Conjugate Market Segments:
As per MRFR report, the global antibody drug conjugate market is segmented on the basis of type, product, technology, application and end-user.
Based on type, it is segmented into drug/toxin, linker, monoclonal antibodies and others. Of these, the antibody drug conjugate linker is expected to have the maximum share in the antibody drug conjugate market.
Based on application, the antibody drug conjugate market is segmented into lymphoma, multiple myeloma, solid tumors, skin cancer, breast cancer, colon cancer, lung cancer, glioblastoma, ovary cancer, pancreas cancer, kidney cancer, prostate cancer and leukemia. Leukemia is further segmented into Chronic Lymphocytic Leukemia (CLL), Acute Lymphocytic Leukemia (ALL), Chronic Myeloid Leukemia (CML), and Acute Myeloid Leukemia (AML). Of these, breast cancer had the maximum share owing to its increasing prevalence.
Based on product, it is segmented into Kadcyla, Adcertis and others.
Based on technology, the antibody drug conjugate market is segmented into Immunomedics technology, Seattle Genetics technology, ImmunoGen technology and others.
Based on end-user, it is segmented into biopharmaceutical companies, biotechnology companies, academic research institutes, specialized cancer and others.
Regional Analysis:
By region, the Antibody Drug Conjugate market has been segmented into North America, Rest-of-the-World (RoW), Europe, and Asia Pacific (APAC).
Based on region, the antibody drug conjugate market covers growth opportunities and latest trends across North America, Europe, Asia Pacific and Middle East and Africa. Of these, North America is expected to accrue maximum share in the market due to advancement in manufacturing techniques, technological innovation and contribution of nanotechnology to create ADC. The U.S. FDA has given approval to only three ADC. The antibody drug conjugate market in Europe will have the second largest share followed by the APAC region. APAC is an emerging market and the factors that are driving the growth of the market include increasing government initiatives. A good number of products are under the pipeline and such developments are performed under license agreements.
TABLE OF CONTENTS:
Chapter 1. Report Prologue
Chapter 2. Market Introduction
2.1 Definition
2.2 Scope Of The Study
2.2.1 Research Objective
2.2.2 Assumptions
2.2.3 Limitations
Chapter 3. Research Methodology
3.1 Introduction
3.2 Primary Research
3.3 Secondary Research
3.4 Market Size Estimation
Chapter 4. Market Dynamics
4.1 Drivers
4.2 Restraints
4.3 Opportunities
4.4 Challenges
4.5 Macroeconomic Indicators
4.6 Technology Trends & Assessment
Chapter 5. Market Factor Analysis
5.1 Porter’s Five Forces Analysis
5.1.1 Bargaining Power Of Suppliers
5.1.2 Bargaining Power Of Buyers
5.1.3 Threat Of New Entrants
5.1.4 Threat Of Substitutes
5.1.5 Intensity Of Rivalry
5.2 Value Chain Analysis
5.3 Investment Feasibility Analysis
5.4 Pricing Analysis
Chapter 6. Global Antibody Drug Conjugate Market, By Type
6.1 Introduction
6.2 Monoclonal Antibodies
6.2.1 Market Estimates & Forecast, 2017–2023
6.3 Linker
6.3.1 Market Estimates & Forecast, 2017–2023
6.4 Drug/Toxin
6.4.1 Market Estimates & Forecast, 2017–2023
6.5 Others
Chapter 7. Global Antibody Drug Conjugate Market, By Application
7.1 Introduction
7.2 Leukemia
7.2.1 Market Estimates & Forecast, 2017–2023
7.2.2 Acute Myeloid Leukemia (AML)
7.2.2.1 Market Estimates & Forecast, 2017–2023
7.2.3 Chronic Myeloid Leukemia (CML)
7.2.3.1 Market Estimates & Forecast, 2017–2023
7.2.4 Acute Lymphocytic Leukemia (ALL)
7.2.4.1 Market Estimates & Forecast, 2017–2023
7.2.5 Chronic Lymphocytic Leukemia (CLL)
7.2.5.1 Market Estimates & Forecast, 2017–2023
7.3 Prostate Cancer
Continued…
LIST OF TABLES:
Table 1 Global Antibody Drug Conjugate Market, By Region, 2017-2023 (USD Million)
Table 2 North America Antibody Drug Conjugate Market, By Country, 2017-2023 (USD Million)
Table 3 Europe Antibody Drug Conjugate Market, By Country, 2017-2023 (USD Million)
Table 4 Asia-Pacific Antibody Drug Conjugate Market, By Country, 2017-2023 (USD Million)
Table 5 Middle East & Africa Antibody Drug Conjugate Market, By Region, 2017-2023 (USD Million)
Table 6 South America Antibody Drug Conjugate Market, By Region, 2017-2023 (USD Million)
Continued…
LIST OF FIGURES:
FIGURE 1 Research Process Of MRFR
FIGURE 2 Top-Down & Bottom-Up Approach
FIGURE 3 Market Dynamics
FIGURE 4 Impact Analysis: Market Drivers
FIGURE 5 Impact Analysis: Market Restraints
FIGURE 6 Porter’s Five Forces Analysis
FIGURE 7 Value Chain Analysis
Continued…
Browse More Information On This Report at: https://www.marketresearchfuture.com/reports/antibody-drug-conjugate-market-1113
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Info:
Name: abhishek sawant
Email: Send Email
Organization: Market Research Future
Address: Market Research Future Office No. 528,, Amanora Chambers Magarpatta Road, Pune, India.,
Phone: +1 646 845 9312
Website: https://www.marketresearchfuture.com/reports/antibody-drug-conjugate-market-1113
Source: MarketersMedia
Release ID: 88892006
